Comparison of clinical efficiancy of tolterodine or trospium chloride in overactive badder teatment

Abstract

Objective: The aim of the study is to compare the efficiency of trospium cloride and tolterodine in overactive bladder treatment.

Material and Methods: The patients that applied to Zeynep Kamil Educational and Reseach Hospital Gynecology Clinic with one or more of following complains such as nocturia, poliuria (more than 8/day) and urodinamically overactive bladder proved

patients and the patients treated with trospium cloride or tolterodine have been called up at least 3 months after treatment and the day and night urinary frequency and wetness of underwear are investigated.

Results: There is no significiant difference between the demographic characteristics of two groups. There is no statistically differences between two groups in terms of symptoms.

Conclusion: The efficiancy of trospiyum cloride and tolterodine are similar in terms of overactive bladder treatment.

Key words: Overactive bladder, Tolterodine, Trospium Chloride.

Keywords

• Overactive bladder, Tolterodine, Trospium Chloride.CİLT: 45 YIL: 2014 SAYI: 4ZEYNEP KAMİL TIP BÜLTENİ 2014;45:160-64

Aşırı aktif mesane tedavisinde trospiyum klorür ile tolterodin'in klinik etkinliğinin karşılaştırılması

Öz

AMAÇ: Aşırı aktif mesane tedavisinde trospiyum klorür ve tolterodin’in etkinliğini karşılaştırmak.

MATERYAL ve METOD: Zeynep Kamil Eğitim ve Araştırma Hastanesi polikliniğine, ani idrar sıkışması, sık idrara çıkma (günde 8'den fazla), noktüri, idrar kaçırma şikayetlerinden biri veya birkaçı nedeniyle başvuran, ürodinamik olarak aşırı aktif mesane tanısı doğrulanmış ve trospiyum klorür veya tolterodin tedavisine başlanmış olan hastalar, tedavi başlangıcından en az 3 ay sonra geri çağrılarak, gündüz ve gece idrar sıklığı, kaçırılan idrarın çamaşıra etkileri sorgulandı.

BULGULAR: Her iki tedavi grubunun demografik verileri istatistiksel olarak benzer bulundu. Gruplara göre semptomlar arasında istatistiksel olarak anlamlı farklılık izlenmedi.(p>0,05)

SONUÇ: Aşırı aktif mesane tedavisinde trospiyum ve tolterodin etkinlik bakımından benzer oranlara sahiptir.

Anahtar Kelimeler: Aşırı aktif mesane, Tolterodin, trospiyum klorür

Anahtar Kelimeler

• Aşırı aktif mesane, Tolterodin, Trospiyum klorür.

Kaynakça

1. - Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A,Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association;International Continence Society. An International Urogynecological Association(IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20.
2. - Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87 : 760–6
3. -Sarici H, Ozgur BC, Telli O, Doluoglu OG, Eroglu M, Bozkurt S. The prevalence of overactive bladder syndrome and urinary incontinence in a Turkish women population; associated risk factors and effect on Quality of life. Urologia 2014; 22:doi: 10.5301/uro.5000057
4. - Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 335–40
5. -Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distres inventory (UDI-6) in a Turkish population. Neurourol Urodyn. 2007;26(1):129-33.
6. -Cam C, Sancak P, Karahan N, Sancak A, Celik C, Karateke A. Validation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire(PISQ-12) in a Turkish population. Eur J Obstet Gynecol Reprod Biol. 2009Sep;146(1):104-7.. )
7. - Jackson S. The patient with an overactive bladder ± symptoms and quality of life issues. Urology 1997; 50 (Suppl. 6A): 18±22
8. -Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of overactive bladder and effect of treatment with tolterodine. BJU Int 1999; 83: 583±90

9. -Johannesson M, O'Connor RM, Kobelt G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557±62
10. -Brown JS, Subak LL, Gras J, Brown BA, Kuppermann M, Posner SF. Urge incontinence: the patient’s perspective. J Womens Health 1998; 7: 1263–9
11. -Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl.): S580–90
12. - Andersson K.–E. New developments in the management of overactive bladder: focus on
13. mirabegron and onabotulinumtoxinA. Ther Clin risk Manag. 2013; 9: 161–170.
14. -Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 2003; 43: 1–5
15. -Andersson KE, Wein AJ. Pharmacologic Management of Storage and Emptying Failure. In: Campbell-Walsh Urology, 9th ed, Wein AJ, Kavoussi LR, Novick AC, et al (Eds), Saunders Elsevier, Philadelphia 2007. p.2091
16. -Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12:148.
17. - Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543–62
18. - Wood AJJ, Ouslander JG. Management of Overactive Bladder and Urge Urinary Incontinence in the Elderly Patient. Am J Med. 2006; 119: 29- 36.
19. - Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007; 178:978.
20. -Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006; 33:465.
21. - Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005; 48: 5- 26.7
22. -ScheifR, Takeda M. Centralnervous system safety ofanticholinergic drugs for the treatment of overactive bladder in the elderly. 2005; 27: 144- 53
23. - Brynne N, Stahl MM, Hallen B, et al. Pharmokinetics and pharmacodynamics of tolterodine in man. Anew drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35:287-295
24. -Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polmorphism on pharmokinetics and pharmacodynamics of tolterodine. Int J Clin Pharmacol Ther. 1998;63:529-539
25. - Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76:358.
26. - Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78:687.
27. -Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;6:e16718.
28. -Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 2012;18:167-74.
29. -Yu YF, Nichol MB, Yu AP et al: Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005; 8: 495.
30. -Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-93.
31. -Moher, D., K.F. Schulz, and D.G. Altman, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 2001;357(9263): p. 1191- 4.
32. - MacDiarmid SA, Ellsworth PI, Ginsberg DA, et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011; 77:24.
33. - Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013 Jun;51(6):432-41.
34. - Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; :CD003781.
35. - Oelke M, de la Rosette JJ, Michel MC, Jonas U. Medical therapy of urinary incontinence. Internist. 2005; 46: 75- 82.
36. -Güven M, Coşkun A, Güngören A, Özdemir Ö, Ercan Ö, Karakuş S. Aşırı aktif mesane tedavisinde trospiyum klorid ve tolterodinin tedavi etkinlikleri ve yan etkilerinin karşılaştırılması. J Turk Obstet Gynecol Soc 2008; 5 :118- 22